Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-99677 in healthy volunteers
NCT03554993Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- May 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of gamcemetinib in ankylosing spondylitis (AS) (3 arms), sponsored by Celgene Corporation. Primary endpoint: Adverse Events (AEs). Started May 2018; status: completed.
02
Drugs
gamcemetinib
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT03554993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03554993.